ES2334656T3 - Uso de epa y dha en prevencion secundaria de derrames cerebrales. - Google Patents

Uso de epa y dha en prevencion secundaria de derrames cerebrales. Download PDF

Info

Publication number: ES2334656T3
Authority: ES; Spain
Prior art keywords: epa; dha; patients; mixture; fish oil
Prior art date: 2002-05-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES03722833T

Other languages

English (en)

Spanish (es)

Inventor

Philip Calder

Robert Grimble

Patrick Gallagher

Cliff Shearman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pronova Biopharma Norge AS

Original Assignee

Pronova Biopharma Norge AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-03

Filing date

2003-05-02

Publication date

2010-03-15

2003-05-02 Application filed by Pronova Biopharma Norge AS filed Critical Pronova Biopharma Norge AS

2010-03-15 Application granted granted Critical

2010-03-15 Publication of ES2334656T3 publication Critical patent/ES2334656T3/es

2023-05-02 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

210000004556 brain Anatomy 0.000 title claims description 7
230000009863 secondary prevention Effects 0.000 title description 4
239000000203 mixture Substances 0.000 claims abstract description 41
208000024891 symptom Diseases 0.000 claims abstract description 9
238000002360 preparation method Methods 0.000 claims abstract description 5
229940126701 oral medication Drugs 0.000 claims abstract description 4
150000003839 salts Chemical class 0.000 claims abstract description 4
230000002265 prevention Effects 0.000 claims abstract description 3
239000002775 capsule Substances 0.000 claims description 26
239000003814 drug Substances 0.000 claims description 18
239000004480 active ingredient Substances 0.000 claims description 8
239000003963 antioxidant agent Substances 0.000 claims description 3
230000003078 antioxidant effect Effects 0.000 claims description 2
125000004494 ethyl ester group Chemical group 0.000 claims description 2
201000004569 Blindness Diseases 0.000 claims 1
206010001902 amaurosis Diseases 0.000 claims 1
230000000302 ischemic effect Effects 0.000 claims 1
230000001052 transient effect Effects 0.000 claims 1
208000032109 Transient ischaemic attack Diseases 0.000 abstract description 5
201000010875 transient cerebral ischemia Diseases 0.000 abstract description 5
208000007957 amaurosis fugax Diseases 0.000 abstract description 3
MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 70
235000021323 fish oil Nutrition 0.000 description 40
235000020673 eicosapentaenoic acid Nutrition 0.000 description 37
235000020669 docosahexaenoic acid Nutrition 0.000 description 36
229940090949 docosahexaenoic acid Drugs 0.000 description 35
150000002632 lipids Chemical class 0.000 description 31
235000014113 dietary fatty acids Nutrition 0.000 description 23
229930195729 fatty acid Natural products 0.000 description 23
239000000194 fatty acid Substances 0.000 description 23
150000004665 fatty acids Chemical class 0.000 description 23
238000010186 staining Methods 0.000 description 23
235000019486 Sunflower oil Nutrition 0.000 description 18
235000020777 polyunsaturated fatty acids Nutrition 0.000 description 18
239000002600 sunflower oil Substances 0.000 description 18
230000000694 effects Effects 0.000 description 17
DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 17
102000007330 LDL Lipoproteins Human genes 0.000 description 16
108010007622 LDL Lipoproteins Proteins 0.000 description 16
150000003904 phospholipids Chemical class 0.000 description 15
208000037260 Atherosclerotic Plaque Diseases 0.000 description 14
238000009826 distribution Methods 0.000 description 13
210000002540 macrophage Anatomy 0.000 description 13
230000003902 lesion Effects 0.000 description 11
239000003921 oil Substances 0.000 description 11
235000019198 oils Nutrition 0.000 description 11
239000002253 acid Substances 0.000 description 9
201000001320 Atherosclerosis Diseases 0.000 description 8
229940079593 drug Drugs 0.000 description 8
238000001356 surgical procedure Methods 0.000 description 8
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 7
208000006011 Stroke Diseases 0.000 description 7
238000000546 chi-square test Methods 0.000 description 7
235000020778 linoleic acid Nutrition 0.000 description 7
238000000692 Student's t-test Methods 0.000 description 6
208000007536 Thrombosis Diseases 0.000 description 6
238000000540 analysis of variance Methods 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 6
206010003210 Arteriosclerosis Diseases 0.000 description 5
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
210000001367 artery Anatomy 0.000 description 5
230000007423 decrease Effects 0.000 description 5
235000005911 diet Nutrition 0.000 description 5
230000037213 diet Effects 0.000 description 5
238000010348 incorporation Methods 0.000 description 5
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 4
108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 4
102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 4
208000027418 Wounds and injury Diseases 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000008859 change Effects 0.000 description 4
230000006378 damage Effects 0.000 description 4
238000003364 immunohistochemistry Methods 0.000 description 4
208000014674 injury Diseases 0.000 description 4
238000000034 method Methods 0.000 description 4
235000006286 nutrient intake Nutrition 0.000 description 4
230000002787 reinforcement Effects 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
241000283707 Capra Species 0.000 description 3
102000003992 Peroxidases Human genes 0.000 description 3
230000008595 infiltration Effects 0.000 description 3
238000001764 infiltration Methods 0.000 description 3
235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 3
238000002483 medication Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000001338 necrotic effect Effects 0.000 description 3
230000000926 neurological effect Effects 0.000 description 3
235000020660 omega-3 fatty acid Nutrition 0.000 description 3
108040007629 peroxidase activity proteins Proteins 0.000 description 3
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000208818 Helianthus Species 0.000 description 2
235000003222 Helianthus annuus Nutrition 0.000 description 2
101000934372 Homo sapiens Macrosialin Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
102000004895 Lipoproteins Human genes 0.000 description 2
108090001030 Lipoproteins Proteins 0.000 description 2
102100025136 Macrosialin Human genes 0.000 description 2
208000031481 Pathologic Constriction Diseases 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
-1 cholesteryl ester Chemical class 0.000 description 2
229960005135 eicosapentaenoic acid Drugs 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
238000013171 endarterectomy Methods 0.000 description 2
230000003176 fibrotic effect Effects 0.000 description 2
235000013305 food Nutrition 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
235000021313 oleic acid Nutrition 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
230000009467 reduction Effects 0.000 description 2
210000000329 smooth muscle myocyte Anatomy 0.000 description 2
230000036262 stenosis Effects 0.000 description 2
208000037804 stenosis Diseases 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
240000003291 Armoracia rusticana Species 0.000 description 1
235000011330 Armoracia rusticana Nutrition 0.000 description 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
206010005184 Blindness transient Diseases 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
108010038218 Dietary Fish Proteins Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
206010063045 Effusion Diseases 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
238000001265 Jonckheere trend test Methods 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
235000019482 Palm oil Nutrition 0.000 description 1
241000736029 Ruvettus pretiosus Species 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
206010042434 Sudden death Diseases 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000008272 agar Substances 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
JAZBEHYOTPTENJ-JLNKQSITSA-M all-cis-5,8,11,14,17-icosapentaenoate Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O JAZBEHYOTPTENJ-JLNKQSITSA-M 0.000 description 1
JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003288 anthiarrhythmic effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229960004217 benzyl alcohol Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000012742 biochemical analysis Methods 0.000 description 1
230000002308 calcification Effects 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
210000001168 carotid artery common Anatomy 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000008602 contraction Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
238000005265 energy consumption Methods 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
235000020988 fatty fish Nutrition 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
235000019688 fish Nutrition 0.000 description 1
229940013317 fish oils Drugs 0.000 description 1
230000037406 food intake Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
229940027941 immunoglobulin g Drugs 0.000 description 1
238000011532 immunohistochemical staining Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
230000001000 lipidemic effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000011785 micronutrient Substances 0.000 description 1
235000013369 micronutrients Nutrition 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
150000002889 oleic acids Chemical class 0.000 description 1
150000001282 organosilanes Chemical class 0.000 description 1
239000002540 palm oil Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000002304 perfume Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
230000000291 postprandial effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000013517 stratification Methods 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000008719 thickening Effects 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
235000014107 unsaturated dietary fats Nutrition 0.000 description 1
210000005167 vascular cell Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229960005080 warfarin Drugs 0.000 description 1
PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Mycology (AREA)
Polymers & Plastics (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Vascular Medicine (AREA)
Nutrition Science (AREA)
Food Science & Technology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Orthopedics, Nursing, And Contraception (AREA)
Medicinal Preparation (AREA)
Fats And Perfumes (AREA)
Magnetic Resonance Imaging Apparatus (AREA)
Cosmetics (AREA)
Medicines Containing Plant Substances (AREA)

ES03722833T 2002-05-03 2003-05-02 Uso de epa y dha en prevencion secundaria de derrames cerebrales. Expired - Lifetime ES2334656T3 (es)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GBGB0210212.7A GB0210212D0 (en)	2002-05-03	2002-05-03	Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
GB0210212		2002-05-03
GB0307625A GB2388026B (en)	2002-05-03	2003-04-02	Use of epa and dha in secondary prevention of neurological events,particulary strokes
GB0307625		2003-04-02

Publications (1)

Publication Number	Publication Date
ES2334656T3 true ES2334656T3 (es)	2010-03-15

Family

ID=9936057

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES03722833T Expired - Lifetime ES2334656T3 (es)	2002-05-03	2003-05-02	Uso de epa y dha en prevencion secundaria de derrames cerebrales.

Country Status (6)

Country	Link
JP (1)	JP4688203B2 (de)
AT (1)	ATE444745T1 (de)
DE (1)	DE60329588D1 (de)
ES (1)	ES2334656T3 (de)
GB (2)	GB0210212D0 (de)
NZ (1)	NZ536507A (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070149617A1 (en) *	2005-11-14	2007-06-28	Deckelbaum Richard J	Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs
EP1982710B1 (de) *	2006-02-07	2013-12-18	Mochida Pharmaceutical Co., Ltd.	Zusammensetzung zur verhinderung des wiederholten auftretens von apoplexie
EP2046312B1 (de) *	2006-07-14	2020-02-19	Kaydence Pharma AS	Pharmazeutische und nutrazeutische produkte mit vitamin k2
CA2743434C (en)	2008-11-14	2015-04-21	Bomi P. Framroze	A method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosis
ES2894340T3 (es)	2009-03-09	2022-02-14	Basf As	Composiciones que comprenden una mezcla de aceites de ácidos grasos y un tensioactivo, y métodos y usos de las mismas
US9370493B2 (en) *	2009-10-23	2016-06-21	Pronova Biopharma Norge As	Coated capsules and tablets of a fatty acid oil mixture
HK1221119A1 (zh)	2013-03-28	2017-05-26	The Trustees Of Columbia University In The City Of New York	用omega-3甘油酯再灌注促进对用於移植的供体器官的保护
EP3263113A1 (de) *	2016-06-30	2018-01-03	Jürgen Mertin	Anwendung und präparat (enthaltend colecalciferol, omega-3-fettsäure and ginkgo biloba) zur aufrechterhaltung und verbesserung kognitiver funktionen

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2218904A (en) *	1988-05-27	1989-11-29	Renafield Limited	Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid
JP2534557B2 (ja) *	1989-03-30	1996-09-18	全国農業協同組合連合会	肉豚用飼料及び食肉用豚の生産方法
JPH05271685A (ja) *	1991-12-26	1993-10-19	Shokuhin Sangyo High Separeeshiyon Syst Gijutsu Kenkyu Kumiai	高度不飽和脂肪酸含有油脂組成物及び高度不飽和脂肪酸を含有するグリセリド油の製造方法
IT1264987B1 (it) *	1993-12-14	1996-10-17	Prospa Bv	Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono
IT1274734B (it) *	1994-08-25	1997-07-24	Prospa Bv	Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
US6069175A (en) *	1996-11-15	2000-05-30	Pfizer Inc.	Estrogen agonist/antagonists treatment of atherosclerosis
JPH1180083A (ja) *	1997-09-10	1999-03-23	Nof Corp	エイコサペンタエン酸エステルの製造方法
US6153653A (en) *	1997-11-26	2000-11-28	Protarga, Inc.	Choline compositions and uses thereof
US5977174A (en) *	1997-11-26	1999-11-02	Neuromedica, Inc.	Cholinergic compositions and uses thereof
JP2000159678A (ja) *	1998-11-30	2000-06-13	Nof Corp	皮膚外用剤組成物
GB9901809D0 (en) *	1999-01-27	1999-03-17	Scarista Limited	Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
IT1308613B1 (it) *	1999-02-17	2002-01-09	Pharmacia & Upjohn Spa	Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
JP2001131088A (ja) *	1999-11-02	2001-05-15	Kyurin:Kk	シンドロームｘ症候群治療剤
CZ300792B6 (cs) *	2000-05-05	2009-08-12	Applied Research Systems Ars Holding N. V.	Farmaceutický prostredek
US7226916B1 (en) *	2000-05-08	2007-06-05	N.V. Nutricia	Preparation for the prevention and/or treatment of vascular disorders

2002
- 2002-05-03 GB GBGB0210212.7A patent/GB0210212D0/en not_active Ceased
2003
- 2003-04-02 GB GB0307625A patent/GB2388026B/en not_active Expired - Fee Related
- 2003-05-02 DE DE60329588T patent/DE60329588D1/de not_active Expired - Lifetime
- 2003-05-02 NZ NZ536507A patent/NZ536507A/en not_active IP Right Cessation
- 2003-05-02 AT AT03722833T patent/ATE444745T1/de not_active IP Right Cessation
- 2003-05-02 JP JP2004500857A patent/JP4688203B2/ja not_active Expired - Fee Related
- 2003-05-02 ES ES03722833T patent/ES2334656T3/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
NZ536507A (en)	2008-12-24
JP2005529903A (ja)	2005-10-06
GB0210212D0 (en)	2002-06-12
ATE444745T1 (de)	2009-10-15
GB2388026B (en)	2006-02-08
GB2388026A (en)	2003-11-05
GB0307625D0 (en)	2003-05-07
DE60329588D1 (de)	2009-11-19
JP4688203B2 (ja)	2011-05-25

Publication	Publication Date	Title
AU2003229993B2 (en)	2008-07-24	Use of EPA and DHA in secondary prevention
Bao et al.	2020	Therapeutic potentials and modulatory mechanisms of fatty acids in bone
Harris et al.	2008	Stearidonic acid-enriched soybean oil increased the omega-3 index, an emerging cardiovascular risk marker
ES2426132T3 (es)	2013-10-21	Uso del éster etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia
JP5827784B2 (ja)	2015-12-02	ビタミンｋ２を含む医薬及び栄養補助製品
Véricel et al.	2015	Moderate oral supplementation with docosahexaenoic acid improves platelet function and oxidative stress in type 2 diabetic patients
ES2346047T3 (es)	2010-10-08	Composicion antiarteriosclerosis que comprende fitoeno o fitoflueno.
S. Babu, Geraldine V. Mitchell, Paddy Wiesenfeld, Mamie Y. Jenkins, Hemavathi Gowda	2000	Nutritional and hematological impact of dietary flaxseed and defatted flaxseed meal in rats
DK201100096U1 (da)	2011-09-23	Diætformuleringer
Fares et al.	2014	Omega-3 fatty acids: a growing ocean of choices
Yamagata	2020	Prevention of endothelial dysfunction and cardiovascular disease by n-3 fatty acids-inhibiting action on oxidative stress and inflammation
ES2334656T3 (es)	2010-03-15	Uso de epa y dha en prevencion secundaria de derrames cerebrales.
US8729124B2 (en)	2014-05-20	Use of EPA and DHA in secondary prevention
CA2599112A1 (en)	2006-08-17	Composition comprising dihomo-.gamma.-linolenic acid (dgla) as the active ingredient
BRPI0407338B1 (pt)	2016-10-25	nutriente dietético ou suplemento alimentar compreendendo uma composição comestível, bem como uma composição farmacêutica oralmente administrável e respectivos usos
Verveniotis et al.	2018	The impact of omega 3 fatty acids in atherosclerosis and arterial stiffness: an overview of their actions
JP2015091855A (ja)	2015-05-14	アテローム性動脈硬化症の治療のための循環酸化低密度リポタンパク質‐ベータ‐２‐糖タンパク質１複合体を減少させる方法
Raffaelli et al.	2008	N-3 polyunsaturated fatty acid effect in periodontal disease: state of art and possible mechanisms involved
CA2827561A1 (en)	2012-08-23	Omega 3 fatty acid diagniostic assay for the dietary management of patients with cardiovascular disease (cvd)
Mahadik et al.	2006	Phospholipids in schizophrenia
Burgess et al.	1995	Evaluation of four animal models of intrarenal calcium deposition and assessment of the influence of dietary supplementation with essential fatty acids on calcification
ES2934132T3 (es)	2023-02-17	Tratamiento para enfermedades de hígado graso no alcohólico
US20060182828A1 (en)	2006-08-17	Methods of reducing lipid peroxidation and achieving related health benefits by the administration of tocopherol and sesame lignans
CN101756984B (zh)	2012-04-18	吡咯并喹啉醌在治疗和预防动脉粥样硬化中的应用
Oludare et al.	2023	Potential Benefits of Omega 3.5. 7 on Cardiovascular and Reproductive Functions of Male Rats Administered LN G-Nitro Arginine Methyl Ester (L-NAME)